TTC

(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE

Find entries where: TTC

is present as a standalone ligand in 6 entries

as a non-polymer is covalently linked to polymer or other heterogen groups 1 entries

Find related ligands:

Similar Ligands (Stereospecific)

Similar Ligands (Quick Screen)

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
Synonyms	TOPOTECAN, HYCAMTIN
Identifiers	n/a
Formula	C₂₃ H₂₃ N₃ O₅
Molecular Weight	421.446
Type	NON-POLYMER
Isomeric SMILES	CC[C@@]1(C2=C(COC1=O)C(=O)N3Cc4cc5c(ccc(c5CN(C)C)O)nc4C3=C2)O
InChI	InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
InChIKey	UCFGDBYHRUNTLO-QHCPKHFHSA-N

Chemical Details
Formal Charge	0
Atom Count	54
Chiral Atom Count	1
Bond Count	58
Aromatic Bond Count	18

Drug Info: DrugBank

DrugBank ID	DB01030
Name	Topotecan
Groups	approved investigational
Description	An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Synonyms	Topotecanum 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin Topotecan Topotecan hydrochloride Topotecane
Brand Names	Topotecan Hospira Teva-topotecan Topotecan Topotecan Injection Hycamtin Topotecan Actavis Topotecan hydrochloride Topotecan Hydrochloride Topotecan Hydrochloride for Injection Mylan-topotecan Hydrochloride for Injection Topotecan for Injection PMS-topotecan Topotecan Teva Potactasol
Indication	For the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy.
Categories	Alkaloids Antineoplastic Agents Antineoplastic and Immunomodulating Agents BCRP/ABCG2 Substrates Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 CYP3A4 Inhibitors Cytochrome P-450 Enzyme Inhibitors Drugs that are Mainly Renally Excreted Enzyme Inhibitors Immunosuppressive Agents MATE 1 Inhibitors MATE 1 Substrates MATE 1 Substrates with a Narrow Therapeutic Index MATE 2 Substrates MATE 2 Substrates with a Narrow Therapeutic Index MATE inhibitors MATE substrates Myelosuppressive Agents Narrow Therapeutic Index Drugs P-glycoprotein substrates P-glycoprotein substrates with a Narrow Therapeutic Index Topoisomerase 1 (TOP1) inhibitors Topoisomerase I Inhibitors Topoisomerase Inhibitors
ATC-Code	L01CE01
CAS number	123948-87-8

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
DNA topoisomerase 1	MSGDHLHNDSQIEADFRLNDSHKHKDKHKDREHRHKEHKKEKDREKSKHS...	unknown	inhibitor
DNA	-	unknown	intercalation
DNA topoisomerase I, mitochondrial	MRVVRLLRLRAALTLLGEVPRRPASRGVPGSRRTQKGSGARWEKEKHEDG...	unknown	inhibitor
ATP-binding cassette sub-family G member 2	MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKS...	unknown	substrate
P-glycoprotein 1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	substrate
Multidrug and toxin extrusion protein 1	MEAPEEPAPVRGGPEATLEVRGSRCLRLSAFREELRALLVLAGPAFLVQL...	unknown	substrate,inhibitor
Multidrug and toxin extrusion protein 2	MDSLQDTVALDHGGCCPALSRLVPRGFGTEMWTLFALSGPLFLFQVLTFM...	unknown	substrate
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682